Consciousness and Sanofi Establish Strategic Research Collaboration to Develop AI-Driven Precision Drug Pipeline
Collaborative efforts aim to accelerate drug discovery and improve clinical success
Agreement to use the AI-based capabilities and Exscientia’s personalized medicine platform from target identification to patient selection
Research will focus on up to 15 new small molecule candidates in oncology and immunology
Exscientia to receive $ 100 million upfront cash payment with potential of $ 5.2 billion in total milestones plus tiered royalties
PARIS, OXFORD and BOSTON – January 7, 2022 – Sanofi and Exscientia today announced a groundbreaking research collaboration and licensing agreement to develop up to 15 new small molecule candidates in oncology and immunology, leveraging the end-to-end AI platform of Exscientia using samples from real patients. The companies have been working together since 2016 and in 2019 Sanofi fired Exscientia’s new bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
“We are looking forward to deepening our work with Consciousness, a leader in the use of AI to modernize all aspects of drug discovery and development ”, said Frank Nestlé, Global Head of Research and Scientific Director of Sanofi. “Sanofi’s collaboration with Consciousness aims to transform the way we discover and develop new small molecule drugs for cancer and immune-mediated diseases. Applying Sophisticated AI and Machine Learning Methods Will Not Only Reduce Drug Discovery time limit, but will also help to design better quality and better targeted drugs for patients.
Exscientia and Sanofi will collaborate to identify and select target projects, building on Exscientia’s personalized medicine platform. The platform enables a “patient-first” approach by integrating primary human tissue samples into early target research and drug discovery. In doing so, Exscientia scientists can integrate patient, disease, and relevant clinical data into decisions about potential new drug candidates earlier in the drug creation process. In addition to target discovery, Exscientia will lead small molecule drug design and optimization activities through the nomination of development candidates, with Sanofi assuming responsibility for preclinical and clinical development, manufacturing and commercialization. .
“It is extremely exciting to work with Sanofi to realize the full potential of AI to deliver the next generation of cancer drugs and immunology” said Andrew Hopkins, DPhil, CEO and Founder of Exscientia. “Our AI-based platform can be leveraged in drug discovery, translational research and development, with applications ranging from improving precision medicine and the quality of drug candidates to enrichment for patient selection in clinical trials. Our expanded collaboration with Sanofi will use the breadth of our platform to test AI-designed drug candidates against patient tissue models, potentially offering much better accuracy than conventional approaches such as mouse models. When you consider the cash this represents – testing candidates against real humans tissue years before a clinical trial – it’s transformative.
Under the terms of the agreement, Exscientia will receive an initial cash payment of $ 100 million from Sanofi and will be eligible to receive future milestone payments for research, translation, clinical development, regulatory and commercial up to approximately $ 5.2 billion in total, if all milestones for all programs are met. In the event that Sanofi commercializes a therapeutic product resulting from the collaboration, Exscientia will also be eligible to receive tiered royalties on product sales ranging from high to single digits through mid-adolescence and a co-investment option. clinic to increase the royalty rate up to 21% on net sales of co-financed products. The upfront cash payment of $ 100 million is expected to be reflected in Exscientia’s first quarter 2022 financial results as cash inflows from collaborations and recognized as revenue over the term of the agreement.
Exscientia is an AI-driven pharmaceutical company committed to discovering, designing and developing the best possible drugs in the fastest and most efficient way. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to advance AI-designed small molecules in the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precisely designed therapy candidates, with more than 25 projects underway, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
Exscientia has offices in Oxford, Vienna, Dundee, Boston, Miami and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscienceAI.
Sanofi is committed to supporting people in their health challenges. We are a global biopharmaceutical company focused on human health. We prevent disease with vaccines, offer innovative treatments to fight pain and relieve suffering. We support the few people who suffer from rare diseases and the millions of people with long-term chronic diseases.
With more than 100,000 people in 100 countries, Sanofi transforms scientific innovation into healthcare solutions around the world.
Sanofi Press Relations contacts
Phone. : +1 (781) 264-1091
Phone. : +33 (0) 6 25 09 14 25
Sanofi Paris Investor Relations contacts
Contacts Investor Relations Sanofi North America
Phone. : +33 (0) 1 53 77 45 45
Consciousness Contact media relations
Consciousness Investor Relations Contact
Consciousness Forward-looking statements
This press release contains certain forward-looking statements within the meaning of “security Harbor»Provisions of the Private Securities Litigation Reform Act of 1995, including declarations in regards to Exscientia expectations regarding the ability of its AI-backed personalized medicine platform to design and develop new small molecule candidates in oncology and immunology. Words such as “anticipates”, “believes”, “expects”, “intends”, “plans”, “anticipates” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, and no assurance can be given that the AI-backed personalized medicine platform described above will be successful in developing new small molecule candidates in the future. fields of oncology and immunology or to reach any stage of its agreement with Sanofi. Consciousness makes no commitment to publicly update or revise any forward-looking statements, whether Consequently new information, future events or otherwise, except as required by law.
Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “believes”, “plans” and similar expressions. Although Sanofi management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by forward-looking information and statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, future clinical data and analyzes, including postmarketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biologic application that may be filed for such product candidates as well as their decisions regarding labeling and other matters which could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not have commercial success, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to conclude related transactions and / or obtain regulatory authorizations, the risks associated with intellectual property and any litigation in course or related future and the end result of that litigation, trends in exchange rates and interest rates in v rigor, volatile market and economic conditions, cost containment initiatives and subsequent changes, and the impact COVID-19 will have on us, our customers, suppliers, vendors and other business partners, and the financial condition of the country. ‘one of them, as well as our people and the global economy as a whole. Any significant effect of COVID-19 on any of the above could also negatively impact us. This situation is changing quickly and additional impacts may arise that we are not currently aware of and may exacerbate other risks identified previously. Risks and uncertainties also include those uncertainties discussed or identified in public documents filed with the SEC and the AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the Sanofi annual report on Form 20 -F for the fiscal year ended December 31, 2020. Except as required by applicable law, Sanofi does not undertake any obligation to update or revise the information or forward-looking statements.